Drug Profile
Research programme: PDE3 inhibitors - Artesian Therapeutics
Alternative Names: 3QO4; ATI22-107; ATI24-214; heart failure therapeutics - Artesian Therapeutics; Type-3 phosphodiesterase inhibitors - Artesian Therapeutics; β-adrenoreceptor antagonists - Artesian TherapeuticsLatest Information Update: 03 Mar 2014
Price :
$50
*
At a glance
- Originator Artesian Therapeutics
- Class Small molecules
- Mechanism of Action Type 3 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure
Most Recent Events
- 28 Feb 2014 No development reported - Preclinical for Heart failure in USA (unspecified route)
- 19 Apr 2006 This programme is still in active development
- 27 Oct 2005 Artesian Therapeutics has been acquired by Cardiome Pharma